uniQure QURE Business Segments — Laboratory And Development Expense

Similar metrics at other companies

IOVASingle Reportable — Research And Development Expense

$57.37M-13.1%

CAPRSingle Reportable — Research And Development Expense

$27.38M+44.7%

CLDXSingle Reportable — Product Development Expense

$50.16M+55.9%

CLDXSingle Reportable — Product Development Expenses

$40.27M+77.8%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

MMSISingle Reportable — Research And Development Expense

$22.61M+0.6%

Questions, answered.

What is uniQure's business segments — laboratory and development expense?

uniQure (QURE) reported business segments — laboratory and development expense of $14.76M in Q1 2026.

How has uniQure's business segments — laboratory and development expense changed year-over-year?

uniQure's business segments — laboratory and development expense decreased by 7.6% year-over-year, from $15.97M to $14.76M.

What is the long-term trend for uniQure's business segments — laboratory and development expense?

Over 3 years (2022 to 2025), uniQure's business segments — laboratory and development expense has grown at a 9.9% compound annual growth rate (CAGR), from $52.23M to $69.29M.

What does business segments — laboratory and development expense mean?

Captures the direct costs incurred for research, laboratory testing, and clinical development activities within the primary segment. This is a critical indicator of the company's commitment to advancing its pipeline of gene therapies and innovation.